Tenaya Therapeutics adopts amended bylaws with enhanced stockholder nomination procedures

Tenaya Therapeutics, Inc.

Enhanced disclosure requirements for stockholder director nominations and business proposals.
Updated provisions to address universal proxy rules and conform to Delaware General Corporation Law amendments.
Revised procedures for stockholder meetings, quorum, and adjourned meetings.
Clarified exclusive forum provisions and updated director, committee, and officer sections.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Tenaya Therapeutics, Inc.: Amended and restated bylaws to enhance procedural mechanics for stockholder nominations and other business, update DGCL provisions, and make other updates (effective 2023-03-16).

Change: bylaw amendment
Effective: 2023-03-16

Exact text from the filing

On March 16, 2023, the Board of Directors (the “Board”) of Tenaya Therapeutics, Inc. (“Tenaya”) approved Tenaya’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”).

View on SEC.gov

Browse all governance changes →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008934

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.